These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 23668736)

  • 1. The benefits of ivabradine are independent of resting heart rate.
    Riccioni G
    Future Cardiol; 2013 May; 9(3):313-5. PubMed ID: 23668736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ivabradine: the hope for a good treatment of ischemic heart disease.
    Riccioni G
    Curr Med Chem; 2013; 20(14):1817-23. PubMed ID: 23394554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of ivabradine in patients with stable angina receiving β-blockers according to baseline heart rate: an analysis of the ASSOCIATE study.
    Tardif JC; Ponikowski P; Kahan T;
    Int J Cardiol; 2013 Sep; 168(2):789-94. PubMed ID: 23138014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heart rate as a treatable cardiovascular risk factor.
    Tardif JC
    Br Med Bull; 2009; 90():71-84. PubMed ID: 19474056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trimetazidine and the contractile response of dysfunctional myocardium in ischaemic cardiomyopathy.
    Belardinelli R
    Rev Port Cardiol; 2000 Nov; 19 Suppl 5():V35-9. PubMed ID: 11206102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of heart rate in cardiovascular diseases: how the results of the BEAUTIFUL study change clinical practice.
    Bruguera Cortada J; Varela A
    Am J Cardiovasc Drugs; 2009; 9 Suppl 1():9-12. PubMed ID: 20000882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ivabradine: an intelligent drug for the treatment of ischemic heart disease.
    Riccioni G
    Molecules; 2012 Nov; 17(11):13592-604. PubMed ID: 23159921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise.
    Joannides R; Moore N; Iacob M; Compagnon P; Lerebours G; Menard JF; Thuillez C
    Br J Clin Pharmacol; 2006 Feb; 61(2):127-37. PubMed ID: 16433867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. I(f) inhibition in cardiovascular diseases.
    Thollon C; Vilaine JP
    Adv Pharmacol; 2010; 59():53-92. PubMed ID: 20933199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ivabradine: from molecular basis to clinical effectiveness.
    Riccioni G
    Adv Ther; 2010 Mar; 27(3):160-7. PubMed ID: 20419486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heart rate control in an unselected consecutive population of outpatients with stable coronary artery disease: Analysis of the CARDIf Study Cohort.
    Vitale C; Iellamo F; Volterrani M; Lombardi M; Fini M; Banach M; Rosano GM
    Angiology; 2010 Nov; 61(8):763-7. PubMed ID: 20462892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ivabradine: beyond heart rate control.
    Riccioni G; Vitulano N; D'Orazio N
    Adv Ther; 2009 Jan; 26(1):12-24. PubMed ID: 19165437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of ivabradine versus metoprolol in early phases of reperfused anterior myocardial infarction with impaired left ventricular function: preliminary findings.
    Fasullo S; Cannizzaro S; Maringhini G; Ganci F; Giambanco F; Vitale G; Pinto V; Migliore G; Torres D; Sarullo FM; Paterna S; Di Pasquale P
    J Card Fail; 2009 Dec; 15(10):856-63. PubMed ID: 19944362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of an ambulatory population with stable coronary artery disease and importance of heart rate: the PULSAR registry.
    Seabra-Gomes R;
    Rev Port Cardiol; 2010 Apr; 29(4):483-508. PubMed ID: 20734572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heart rate-lowering efficacy and respiratory safety of ivabradine in patients with obstructive airway disease: a randomized, double-blind, placebo-controlled, crossover study.
    Majewski S; Slomka S; Zielinska-Wyderkiewicz E; Ciebiada M; Gorski P
    Am J Cardiovasc Drugs; 2012 Jun; 12(3):179-88. PubMed ID: 22409211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
    Fox K; Ferrari R; Tendera M; Steg PG; Ford I;
    Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ivabradine -- the first selective sinus node I(f) channel inhibitor in the treatment of stable angina.
    Sulfi S; Timmis AD
    Int J Clin Pract; 2006 Feb; 60(2):222-8. PubMed ID: 16451297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.
    Fox K; Ford I; Steg PG; Tendera M; Robertson M; Ferrari R;
    Eur Heart J; 2009 Oct; 30(19):2337-45. PubMed ID: 19720635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resting heart rate in cardiovascular disease.
    Fox K; Borer JS; Camm AJ; Danchin N; Ferrari R; Lopez Sendon JL; Steg PG; Tardif JC; Tavazzi L; Tendera M;
    J Am Coll Cardiol; 2007 Aug; 50(9):823-30. PubMed ID: 17719466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of heart rate reduction with ivabradine on exercise-induced myocardial ischemia and stunning.
    Monnet X; Ghaleh B; Colin P; de Curzon OP; Giudicelli JF; Berdeaux A
    J Pharmacol Exp Ther; 2001 Dec; 299(3):1133-9. PubMed ID: 11714904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.